Key takeaways
- Copper tripeptide-1 is sold as a topical cosmetic ingredient, marketed under the brand YVTYVT Copper Peptides Facial Serum.
- Its labeling describes cosmetic skin benefits rather than a treated medical condition.
- No boxed warning is associated with this product's labeling.
- Two registered trials reference related research, including a Phase 2 study on topical wound healing.
- No FAERS adverse event reports were available in the data reviewed.
What Copper Tripeptide-1 Is
Copper tripeptide-1, also known as GHK-Cu, is a small copper-binding peptide compound classified under the pharmacologic label of a methylating agent. It is formulated into topical products intended for skin application rather than systemic use.
What Copper Tripeptide-1 Is Approved For
Labeling for this product describes cosmetic claims: it is marketed to repair and tighten skin, combat visible signs of premature aging, and restore skin's natural density and firmness. These are cosmetic-use descriptions rather than claims tied to a diagnosed medical condition. The product is sold under the brand name YVTYVT Copper Peptides Facial Serum. No boxed warning appears in its labeling.
What the Evidence Shows
Two trials in the clinical trial registry relate to this compound or its research applications. One completed study examined an AI-personalized skincare regimen for facial photoaging in women. A separate Phase 2 trial, currently recruiting, is evaluating a topical GHK-Cu gel for acute skin wound healing.
Reported Side Effects
No adverse event reports were available in the data reviewed for this compound.